Hypera’s Surprise R$1.5 Billion Capital Raise Divides Wall Street and Fuels Pharma M&A Speculation

Key Points

• Hypera, maker of Buscopan and Benegrip, announced an unexpected R$1.5 billion (~$290 million) equity raise at a 17% discount, sending shares down 10.3% and wiping R$1.6 billion (~$310 million) from its market value
• The move comes weeks before binding bids are due for Sanofi’s Medley generics unit — a US$500 million-plus deal that could reshape Brazil’s pharmaceutical landscape — and just as semaglutide’s patent expires, opening a multi-billion-real generic Ozempic market
• Major banks are sharply divided: JPMorgan raised its price target to R$33 (~$6), while BTG Pactual called it “bitter deleveraging” that signals the company cannot reduce debt on its own

Hypera blindsided investors on February 3 by approving a private issuance of up to 70.6 million new shares at R$21.25 (~$4) each — a 17% discount to market — raising up to R$1.5 billion (~$290 million) to cut into its R$7.3 billion (~$1.4 billion) net debt pile.

The Votorantim Group, holding 11% of the company, committed up to R$1 billion (~$190 million) as anchor investor, a move Brazil Journal reported is designed to grow Votorantim’s stake closer to that of founding family vehicles Júnior and Maiorem, which together control 42%.

The timing is loaded. Sanofi’s sale of Medley, its Brazilian generics arm with R$1.3 billion (~$250 million) in revenue and 300 million units of annual production capacity, enters its final phase this month.

Six bidders — EMS, Aché, Biolab, Hypera, Sun Pharma, and a Vinci Compass fund — must submit binding offers by March 13.

Sanofi has set a US$500 million floor and will conduct a same-day mini-auction. EMS and Aché are considered frontrunners, though Hypera’s fresh capital keeps it in the conversation.

Hypera navigates debt amid high rates

The capital raise also lands as Brazil’s Selic rate sits at 15%, punishing leveraged companies. Goldman Sachs projects virtually zero organic debt reduction for Hypera in 2026 given elevated interest costs and capital expenditure, reinforcing its neutral stance with a R$25 (~$5) target.

JPMorgan counters that the raise cuts net debt-to-EBITDA from 2.5x to 2.0x, saving R$150 million (~$29 million) annually in interest — roughly 8% of profit — and raised its target to R$33 (~$6).

Market-aligned analysts see pragmatic balance sheet management ahead of expected rate cuts to around 12% by year-end. Critics on both sides of the political spectrum question whether controlling shareholders are diluting minorities to consolidate power.

Meanwhile, progressive voices note that a stronger Hypera better positions the company to launch generic semaglutide when Ozempic’s Brazilian patent expires in March.

This could potentially expand affordable access to diabetes and obesity treatment in a country where the public health system serves 150 million people.

Hypera reports Q4 results on March 12. The market will be listening closely.

Related coverage: Brazil’s Morning Call | Brazil’s Trade Surplus Doubles in January as Economic Slowdo This is part of The Rio Times’ daily coverage of Latin American news and financial markets.

This article was produced by The Rio Times’ automated newsroom system. How we use AI · Report an error